<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00605384</url>
  </required_header>
  <id_info>
    <org_study_id>AI463-137</org_study_id>
    <nct_id>NCT00605384</nct_id>
  </id_info>
  <brief_title>A Phase IIIb Study to Compare Entecavir Plus Tenofovir vs. Adefovir Added to Continuing Lamivudine Therapy in Adult Patients With Lamivudine-Resistant Hepatitis B Infection</brief_title>
  <official_title>A Comparative Study of the Antiviral Efficacy and Safety of Entecavir Plus Tenofovir Versus Adefovir Added to Continuing Lamivudine in Adults With Lamivudine- Resistant Chronic Hepatitis B Virus Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this clinical research study is to find out whether a combination of entecavir
      (ETV) plus tenofovir (TNF) works better against Hepatitis B virus than adefovir (ADV) added
      to continuing lamivudine (LVD) therapy in patients whose Hepatitis B virus (HBV) is resistant
      against lamivudine. The safety of this treatment will also be studied.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Business Objectives Have Changed
  </why_stopped>
  <start_date>August 2008</start_date>
  <completion_date type="Actual">February 2009</completion_date>
  <primary_completion_date type="Actual">February 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants Who Achieved an Hepatitis B Virus DNA (HBV DNA) Level &lt; 50 IU/mL at Week 48</measure>
    <time_frame>Week 48</time_frame>
    <description>using the Roche COBAS® TaqMan HBV Test for use with the High Pure System (HPS) assay, by Polymerase Chain Reaction (PCR); HBV DNA &lt; 50 IU/mL = approximately 300 copies/mL</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Achieved an HBV DNA Level &lt;50 IU/mL at Week 96</measure>
    <time_frame>Week 96</time_frame>
    <description>by PCR, using the Roche COBAS®TaqMan - HPS assay; HBV DNA &lt; 50 IU/mL = approximately 300 copies/mL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), and Discontinuations Due to AEs or Laboratory Abnormalities</measure>
    <time_frame>Day 1 through end of treatment (Week 100 +/- 5 days)</time_frame>
    <description>AE=any new untoward medical occurrence or worsening of a pre-existing medical condition which does not necessarily have a causal relationship with this treatment. Related AE=relationship of certain, probable, possible, or missing. SAE=any untoward medical occurrence that at any dose: results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, and/or is an important medical event.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Achieved HBV DNA &lt; the Lower Limit of Detection (LLD) at Weeks 48 and 96</measure>
    <time_frame>Week 48, Week 96</time_frame>
    <description>by PCR, using the Roche for the Roche COBAS® TaqMan - HPS assay. LLD = 4.8 IU/mL (approximately 28 copies/mL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HBV DNA Values at Weeks 48 and 96</measure>
    <time_frame>Weeks 48, Week 96</time_frame>
    <description>Number of Participants with HBV DNA &lt;LLD (4.8); LLD to &lt;50; 50 to &lt;172; 172 to &lt;1,720; 1,720 to &lt;17,200; and ≥17,200 IU/mL (&lt;LLD (28); 28 to &lt;300; 300 to &lt;1,000; 1,000 to &lt;10,000; 10,000 to &lt;100,000; and ≥100,000 copies/mL by PCR, using the Roche COBAS®TaqMan - HPS assay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean log10 Reduction From Baseline in HBV DNA at Weeks 48 and 96</measure>
    <time_frame>Week 48, Week 96</time_frame>
    <description>by PCR, using the Roche COBAS®TaqMan - HPS assay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Alanine Aminotransferase (ALT) &gt; 1 x Upper Limit of Normal (ULN) at Baseline Who Achieved ALT Normalization (≤ 1 x ULN) at Weeks 48 and 96</measure>
    <time_frame>Week 48, Week 96</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Were Hepatitis B E-antigen (HBeAg)-Positive at Baseline With Loss of HBeAg at Weeks 48 and 96</measure>
    <time_frame>Baseline, Week 48, Week 96</time_frame>
    <description>HBeAg is a hepatitis B viral protein. It is an indicator of active viral replication.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Were HBeAg-positive at Baseline With HBe Seroconversion at Weeks 48 and 96</measure>
    <time_frame>Baseline, Week 48, Week 96</time_frame>
    <description>HBe seroconversion = HBeAg loss and presence of hepatitis B e-antibody (HBeAb)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Hepatitis-B-Virus Surface Antigen of the (HBsAg) Loss at Weeks 48 and 96</measure>
    <time_frame>Week 48, Week 96</time_frame>
    <description>Hepatitis B surface antigen (HBsAg) = a part of the hepatitis B virus that, when in the blood, is an early marker of infection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With HBs Seroconversion (HBsAg Loss and Presence of HBsAb) at Weeks 48 and 96</measure>
    <time_frame>Week 48, Week 96</time_frame>
    <description>Hepatitis B surface antigen (HBsAg) = a part of the hepatitis B virus that, when in the blood, is an early marker of infection. HBsAb = HBsAg antibodies. HBs Seroconversion = HBsAg loss and presence of HBseAb</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Genotypic Resistance Based on Analysis of Samples From Participants With HBV DNA ≥ 50 IU/mL at Weeks 48 and 96</measure>
    <time_frame>Week 48, Week 96</time_frame>
    <description>HBV DNA ≥ 50 IU/mL = approximately 300 copies/mL</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">4</enrollment>
  <condition>Chronic Hepatitis B</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Entecavir + Tenofovir</intervention_name>
    <description>Tablets, Oral Entecavir 1 mg + Tenofovir 300 mg, once daily, 100 weeks</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Baraclude</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Adefovir + continuing Lamivudine</intervention_name>
    <description>Tablets, Oral, Adefovir 10 mg + Lamivudine, 100 mg, once daily, 100 weeks</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Chronic HBV infection

          -  History of lamivudine (LVD) treatment, and lamivudine resistance (LVDr), receiving LVD
             at screening visit

          -  Compensated liver function

          -  HBV DNA ≥ 172,000 IU/mL

          -  Hepatitis B e-antigen (HBeAg)-positive or HBeAg-negative

        Exclusion Criteria:

          -  Evidence of decompensated cirrhosis

          -  Coinfection with human immunodeficiency virus (HIV), hepatitis C virus (HCV), or
             hepatitis D virus (HDV)

          -  Recent history of pancreatitis

          -  Serum alpha fetoprotein &gt; 100 ng/mL

          -  Except lamivudine, any prior therapy with nucleoside or nucleotide analogue antiviral
             agents with activity against hepatitis B
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cedars Sinai Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente Medical Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rush University Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10025</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Bruxelles</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Bonn</city>
        <zip>53105</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Duesseldorf</city>
        <zip>40237</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Mainz</city>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Messina</city>
        <zip>98124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Modena</city>
        <zip>41100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Naples</city>
        <zip>80135</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Padova</city>
        <zip>35128</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>San Giovanni Rotondo</city>
        <zip>71013</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Chorzow</city>
        <zip>41-500</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Krakow</city>
        <zip>31-531</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Lublin</city>
        <zip>20-089</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Ankara</city>
        <zip>06010</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Ankara</city>
        <zip>06620</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Istanbul</city>
        <zip>34093</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Istanbul</city>
        <zip>34098</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Istanbul</city>
        <zip>34360</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Istanbul</city>
        <zip>34460</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Istanbul</city>
        <zip>34722</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Izmir</city>
        <zip>35100</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Kocaeli</city>
        <zip>41380</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Sihhiye Ankara</city>
        <zip>06100</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Trabzon</city>
        <zip>61080</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Poland</country>
    <country>Turkey</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.fda.gov/MEDWATCH/safety.htm</url>
    <description>For FDA Safety Alerts and Recalls refer to the following link: http://www.fda.gov/MEDWATCH/safety.htm</description>
  </link>
  <verification_date>November 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 18, 2008</study_first_submitted>
  <study_first_submitted_qc>January 30, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 31, 2008</study_first_posted>
  <results_first_submitted>July 13, 2010</results_first_submitted>
  <results_first_submitted_qc>July 13, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 10, 2010</results_first_posted>
  <last_update_submitted>November 15, 2010</last_update_submitted>
  <last_update_submitted_qc>November 15, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 23, 2010</last_update_posted>
  <responsible_party>
    <name_title>Study Director</name_title>
    <organization>Bristol-Myers Squibb</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis B, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tenofovir</mesh_term>
    <mesh_term>Lamivudine</mesh_term>
    <mesh_term>Entecavir</mesh_term>
    <mesh_term>Adefovir</mesh_term>
    <mesh_term>Adefovir dipivoxil</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>A total of 84 subjects were to be treated with entecavir (ETV) plus tenofovir (TNF) or adefovir (ADV) added to continuing lamivudine (LVD).</recruitment_details>
      <pre_assignment_details>Of the 4 subjects enrolled, 2 were not randomized (reasons: “Subject no longer meets study criteria” and “Other”). Both subjects randomized were treated as well.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Entecavir + Tenofovir</title>
          <description>Tablets, Oral, Entecavir 1 mg + Tenofovir 300 mg, once daily, 100 weeks</description>
        </group>
        <group group_id="P2">
          <title>Adefovir + Continuing Lamivudine</title>
          <description>Tablets, Oral, Adefovir 10 mg + Lamivudine, 100 mg, once daily, 100 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0">study terminated early</participants>
                <participants group_id="P2" count="0">study terminated early</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Entecavir + Tenofovir</title>
          <description>Tablets, Oral, Entecavir 1 mg + Tenofovir 300 mg, once daily, 100 weeks</description>
        </group>
        <group group_id="B2">
          <title>Adefovir + Continuing Lamivudine</title>
          <description>Tablets, Oral, Adefovir 10 mg + Lamivudine, 100 mg, once daily, 100 weeks</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1"/>
            <count group_id="B2" value="1"/>
            <count group_id="B3" value="2"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Who Achieved an Hepatitis B Virus DNA (HBV DNA) Level &lt; 50 IU/mL at Week 48</title>
        <description>using the Roche COBAS® TaqMan HBV Test for use with the High Pure System (HPS) assay, by Polymerase Chain Reaction (PCR); HBV DNA &lt; 50 IU/mL = approximately 300 copies/mL</description>
        <time_frame>Week 48</time_frame>
        <population>Due to early study termination, none of the efficacy endpoints were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Entecavir + Tenofovir</title>
            <description>Tablets, Oral, Entecavir 1 mg + Tenofovir 300 mg, once daily, 100 weeks</description>
          </group>
          <group group_id="O2">
            <title>Adefovir + Continuing Lamivudine</title>
            <description>Tablets, Oral, Adefovir 10 mg + Lamivudine, 100 mg, once daily, 100 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Achieved an Hepatitis B Virus DNA (HBV DNA) Level &lt; 50 IU/mL at Week 48</title>
          <description>using the Roche COBAS® TaqMan HBV Test for use with the High Pure System (HPS) assay, by Polymerase Chain Reaction (PCR); HBV DNA &lt; 50 IU/mL = approximately 300 copies/mL</description>
          <population>Due to early study termination, none of the efficacy endpoints were analyzed.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Achieved an HBV DNA Level &lt;50 IU/mL at Week 96</title>
        <description>by PCR, using the Roche COBAS®TaqMan - HPS assay; HBV DNA &lt; 50 IU/mL = approximately 300 copies/mL.</description>
        <time_frame>Week 96</time_frame>
        <population>Due to early study termination, none of the efficacy endpoints were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Entecavir + Tenofovir</title>
            <description>Tablets, Oral, Entecavir 1 mg + Tenofovir 300 mg, once daily, 100 weeks</description>
          </group>
          <group group_id="O2">
            <title>Adefovir + Continuing Lamivudine</title>
            <description>Tablets, Oral, Adefovir 10 mg + Lamivudine, 100 mg, once daily, 100 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Achieved an HBV DNA Level &lt;50 IU/mL at Week 96</title>
          <description>by PCR, using the Roche COBAS®TaqMan - HPS assay; HBV DNA &lt; 50 IU/mL = approximately 300 copies/mL.</description>
          <population>Due to early study termination, none of the efficacy endpoints were analyzed.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), and Discontinuations Due to AEs or Laboratory Abnormalities</title>
        <description>AE=any new untoward medical occurrence or worsening of a pre-existing medical condition which does not necessarily have a causal relationship with this treatment. Related AE=relationship of certain, probable, possible, or missing. SAE=any untoward medical occurrence that at any dose: results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, and/or is an important medical event.</description>
        <time_frame>Day 1 through end of treatment (Week 100 +/- 5 days)</time_frame>
        <population>All treated participants. Timeframe for Outcome Measure revised due to study termination. (Study Completion Date=February 2009).</population>
        <group_list>
          <group group_id="O1">
            <title>Entecavir + Tenofovir</title>
            <description>Tablets, Oral, Entecavir 1 mg + Tenofovir 300 mg, once daily, 100 weeks</description>
          </group>
          <group group_id="O2">
            <title>Adefovir + Continuing Lamivudine</title>
            <description>Tablets, Oral, Adefovir 10 mg + Lamivudine, 100 mg, once daily, 100 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), and Discontinuations Due to AEs or Laboratory Abnormalities</title>
          <description>AE=any new untoward medical occurrence or worsening of a pre-existing medical condition which does not necessarily have a causal relationship with this treatment. Related AE=relationship of certain, probable, possible, or missing. SAE=any untoward medical occurrence that at any dose: results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, and/or is an important medical event.</description>
          <population>All treated participants. Timeframe for Outcome Measure revised due to study termination. (Study Completion Date=February 2009).</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Deaths</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Discontinuations due to AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Discontinuations due to Laboratory Abnormalities</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Achieved HBV DNA &lt; the Lower Limit of Detection (LLD) at Weeks 48 and 96</title>
        <description>by PCR, using the Roche for the Roche COBAS® TaqMan - HPS assay. LLD = 4.8 IU/mL (approximately 28 copies/mL)</description>
        <time_frame>Week 48, Week 96</time_frame>
        <population>Due to early study termination, none of the efficacy endpoints were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Entecavir + Tenofovir</title>
            <description>Tablets, Oral, Entecavir 1 mg + Tenofovir 300 mg, once daily, 100 weeks</description>
          </group>
          <group group_id="O2">
            <title>Adefovir + Continuing Lamivudine</title>
            <description>Tablets, Oral, Adefovir 10 mg + Lamivudine, 100 mg, once daily, 100 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Achieved HBV DNA &lt; the Lower Limit of Detection (LLD) at Weeks 48 and 96</title>
          <description>by PCR, using the Roche for the Roche COBAS® TaqMan - HPS assay. LLD = 4.8 IU/mL (approximately 28 copies/mL)</description>
          <population>Due to early study termination, none of the efficacy endpoints were analyzed.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>HBV DNA Values at Weeks 48 and 96</title>
        <description>Number of Participants with HBV DNA &lt;LLD (4.8); LLD to &lt;50; 50 to &lt;172; 172 to &lt;1,720; 1,720 to &lt;17,200; and ≥17,200 IU/mL (&lt;LLD (28); 28 to &lt;300; 300 to &lt;1,000; 1,000 to &lt;10,000; 10,000 to &lt;100,000; and ≥100,000 copies/mL by PCR, using the Roche COBAS®TaqMan - HPS assay</description>
        <time_frame>Weeks 48, Week 96</time_frame>
        <population>Due to early study termination, none of the efficacy endpoints were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Entecavir + Tenofovir</title>
            <description>Tablets, Oral, Entecavir 1 mg + Tenofovir 300 mg, once daily, 100 weeks</description>
          </group>
          <group group_id="O2">
            <title>Adefovir + Continuing Lamivudine</title>
            <description>Tablets, Oral, Adefovir 10 mg + Lamivudine, 100 mg, once daily, 100 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>HBV DNA Values at Weeks 48 and 96</title>
          <description>Number of Participants with HBV DNA &lt;LLD (4.8); LLD to &lt;50; 50 to &lt;172; 172 to &lt;1,720; 1,720 to &lt;17,200; and ≥17,200 IU/mL (&lt;LLD (28); 28 to &lt;300; 300 to &lt;1,000; 1,000 to &lt;10,000; 10,000 to &lt;100,000; and ≥100,000 copies/mL by PCR, using the Roche COBAS®TaqMan - HPS assay</description>
          <population>Due to early study termination, none of the efficacy endpoints were analyzed.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean log10 Reduction From Baseline in HBV DNA at Weeks 48 and 96</title>
        <description>by PCR, using the Roche COBAS®TaqMan - HPS assay</description>
        <time_frame>Week 48, Week 96</time_frame>
        <population>Due to early study termination, none of the efficacy endpoints was analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Entecavir + Tenofovir</title>
            <description>Tablets, Oral, Entecavir 1 mg + Tenofovir 300 mg, once daily, 100 weeks</description>
          </group>
          <group group_id="O2">
            <title>Adefovir + Continuing Lamivudine</title>
            <description>Tablets, Oral, Adefovir 10 mg + Lamivudine, 100 mg, once daily, 100 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Mean log10 Reduction From Baseline in HBV DNA at Weeks 48 and 96</title>
          <description>by PCR, using the Roche COBAS®TaqMan - HPS assay</description>
          <population>Due to early study termination, none of the efficacy endpoints was analyzed.</population>
          <units>log10</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Alanine Aminotransferase (ALT) &gt; 1 x Upper Limit of Normal (ULN) at Baseline Who Achieved ALT Normalization (≤ 1 x ULN) at Weeks 48 and 96</title>
        <time_frame>Week 48, Week 96</time_frame>
        <population>Due to early study termination, none of the efficacy endpoints were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Entecavir + Tenofovir</title>
            <description>Tablets, Oral, Entecavir 1 mg + Tenofovir 300 mg, once daily, 100 weeks</description>
          </group>
          <group group_id="O2">
            <title>Adefovir + Continuing Lamivudine</title>
            <description>Tablets, Oral, Adefovir 10 mg + Lamivudine, 100 mg, once daily, 100 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Alanine Aminotransferase (ALT) &gt; 1 x Upper Limit of Normal (ULN) at Baseline Who Achieved ALT Normalization (≤ 1 x ULN) at Weeks 48 and 96</title>
          <population>Due to early study termination, none of the efficacy endpoints were analyzed.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Were Hepatitis B E-antigen (HBeAg)-Positive at Baseline With Loss of HBeAg at Weeks 48 and 96</title>
        <description>HBeAg is a hepatitis B viral protein. It is an indicator of active viral replication.</description>
        <time_frame>Baseline, Week 48, Week 96</time_frame>
        <population>Due to early study termination, none of the efficacy endpoints was analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Entecavir + Tenofovir</title>
            <description>Tablets, Oral, Entecavir 1 mg + Tenofovir 300 mg, once daily, 100 weeks</description>
          </group>
          <group group_id="O2">
            <title>Adefovir + Continuing Lamivudine</title>
            <description>Tablets, Oral, Adefovir 10 mg + Lamivudine, 100 mg, once daily, 100 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Were Hepatitis B E-antigen (HBeAg)-Positive at Baseline With Loss of HBeAg at Weeks 48 and 96</title>
          <description>HBeAg is a hepatitis B viral protein. It is an indicator of active viral replication.</description>
          <population>Due to early study termination, none of the efficacy endpoints was analyzed.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Were HBeAg-positive at Baseline With HBe Seroconversion at Weeks 48 and 96</title>
        <description>HBe seroconversion = HBeAg loss and presence of hepatitis B e-antibody (HBeAb)</description>
        <time_frame>Baseline, Week 48, Week 96</time_frame>
        <population>Due to early study termination, none of the efficacy endpoints were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Entecavir + Tenofovir</title>
            <description>Tablets, Oral, Entecavir 1 mg + Tenofovir 300 mg, once daily, 100 weeks</description>
          </group>
          <group group_id="O2">
            <title>Adefovir + Continuing Lamivudine</title>
            <description>Tablets, Oral, Adefovir 10 mg + Lamivudine, 100 mg, once daily, 100 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Were HBeAg-positive at Baseline With HBe Seroconversion at Weeks 48 and 96</title>
          <description>HBe seroconversion = HBeAg loss and presence of hepatitis B e-antibody (HBeAb)</description>
          <population>Due to early study termination, none of the efficacy endpoints were analyzed.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Hepatitis-B-Virus Surface Antigen of the (HBsAg) Loss at Weeks 48 and 96</title>
        <description>Hepatitis B surface antigen (HBsAg) = a part of the hepatitis B virus that, when in the blood, is an early marker of infection</description>
        <time_frame>Week 48, Week 96</time_frame>
        <population>Due to early study termination, none of the efficacy endpoints were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Entecavir + Tenofovir</title>
            <description>Tablets, Oral, Entecavir 1 mg + Tenofovir 300 mg, once daily, 100 weeks</description>
          </group>
          <group group_id="O2">
            <title>Adefovir + Continuing Lamivudine</title>
            <description>Tablets, Oral, Adefovir 10 mg + Lamivudine, 100 mg, once daily, 100 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Hepatitis-B-Virus Surface Antigen of the (HBsAg) Loss at Weeks 48 and 96</title>
          <description>Hepatitis B surface antigen (HBsAg) = a part of the hepatitis B virus that, when in the blood, is an early marker of infection</description>
          <population>Due to early study termination, none of the efficacy endpoints were analyzed.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With HBs Seroconversion (HBsAg Loss and Presence of HBsAb) at Weeks 48 and 96</title>
        <description>Hepatitis B surface antigen (HBsAg) = a part of the hepatitis B virus that, when in the blood, is an early marker of infection. HBsAb = HBsAg antibodies. HBs Seroconversion = HBsAg loss and presence of HBseAb</description>
        <time_frame>Week 48, Week 96</time_frame>
        <population>Due to early study termination, none of the efficacy endpoints were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Entecavir + Tenofovir</title>
            <description>Tablets, Oral, Entecavir 1 mg + Tenofovir 300 mg, once daily, 100 weeks</description>
          </group>
          <group group_id="O2">
            <title>Adefovir + Continuing Lamivudine</title>
            <description>Tablets, Oral, Adefovir 10 mg + Lamivudine, 100 mg, once daily, 100 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With HBs Seroconversion (HBsAg Loss and Presence of HBsAb) at Weeks 48 and 96</title>
          <description>Hepatitis B surface antigen (HBsAg) = a part of the hepatitis B virus that, when in the blood, is an early marker of infection. HBsAb = HBsAg antibodies. HBs Seroconversion = HBsAg loss and presence of HBseAb</description>
          <population>Due to early study termination, none of the efficacy endpoints were analyzed.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Genotypic Resistance Based on Analysis of Samples From Participants With HBV DNA ≥ 50 IU/mL at Weeks 48 and 96</title>
        <description>HBV DNA ≥ 50 IU/mL = approximately 300 copies/mL</description>
        <time_frame>Week 48, Week 96</time_frame>
        <population>Due to early study termination, none of the efficacy endpoints were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Entecavir + Tenofovir</title>
            <description>Tablets, Oral, Entecavir 1 mg + Tenofovir 300 mg, once daily, 100 weeks</description>
          </group>
          <group group_id="O2">
            <title>Adefovir + Continuing Lamivudine</title>
            <description>Tablets, Oral, Adefovir 10 mg + Lamivudine, 100 mg, once daily, 100 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Genotypic Resistance Based on Analysis of Samples From Participants With HBV DNA ≥ 50 IU/mL at Weeks 48 and 96</title>
          <description>HBV DNA ≥ 50 IU/mL = approximately 300 copies/mL</description>
          <population>Due to early study termination, none of the efficacy endpoints were analyzed.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Entecavir + Tenofovir</title>
          <description>Tablets, Oral, Entecavir 1 mg + Tenofovir 300 mg, once daily, 100 weeks</description>
        </group>
        <group group_id="E2">
          <title>Adefovir + Continuing Lamivudine</title>
          <description>Tablets, Oral, Adefovir 10 mg + Lamivudine, 100 mg, once daily, 100 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperchlorhydria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Following review of business priorities, BMS decided to terminate this study at an early stage. This was a strategic decision, not based on clinical or safety concerns. Due to limited data, no conclusions on safety and efficacy can be made.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>BMS Study Director</name_or_title>
      <organization>Bristol-Myers Squibb</organization>
      <email>Clinical.Trials@bms.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

